CPA
ZNTL icon

Capital Performance Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Capital Performance Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-78
Closed -$287 – 2768
2024
Q3 		$287 Buy
+78
New +$283 ﹤0.01% 2472

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Performance Advisors's ZNTL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 78 shares — an estimated $287 sold.

Capital Performance Advisors first reported a position in ZNTL in Q3 2024 and held it in 1 quarter. The position peaked at $287 in Q3 2024. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 78 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $287.
  • Capital Performance Advisors first reported a position in Zentalis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Zentalis Pharmaceuticals position peaked at $287 in Q3 2024.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.